TCGA-OR-A5LN-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.464
- INTERFERON_GAMMA_RESPONSE+0.314
- INTERFERON_ALPHA_RESPONSE+0.307
- IL2_STAT5_SIGNALING+0.260
- INFLAMMATORY_RESPONSE+0.255
- OXIDATIVE_PHOSPHORYLATION+0.219
- IL6_JAK_STAT3_SIGNALING+0.212
- COMPLEMENT+0.180
- KRAS_SIGNALING_UP+0.161
- APICAL_SURFACE+0.116
Top 10 suppressed
- G2M_CHECKPOINT-0.458
- E2F_TARGETS-0.451
- MYC_TARGETS_V2-0.370
- MYC_TARGETS_V1-0.350
- MTORC1_SIGNALING-0.335
- MITOTIC_SPINDLE-0.302
- HEDGEHOG_SIGNALING-0.296
- UNFOLDED_PROTEIN_RESPONSE-0.293
- SPERMATOGENESIS-0.240
- NOTCH_SIGNALING-0.225
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.858 |
| 2 | SRR665670 | GTEX | — | 0.849 |
| 3 | MDT-AP-0377 | Med | Medulloblastoma | 0.848 |
| 4 | SRR2932840 | — | — | 0.840 |
| 5 | 20050035.Her2HRneg | — | D | 0.835 |
| 6 | SRR13780265 | — | cohortMD2 | 0.834 |
| 7 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.827 |
| 8 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.825 |
| 9 | MNG580 | — | — | 0.825 |
| 10 | SRR2778078 | — | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.464 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.314 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.307 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.255 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.219 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.212 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.161 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.116 | Temsirolimus | — uncovered |
| COAGULATION | 0.111 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.073 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.064 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.052 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.021 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.017 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.009 | Idelalisib | — uncovered |